CLINICAL TRIALS PROFILE FOR SIVEXTRO
✉ Email this page to a colleague
All Clinical Trials for sivextro
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02342418 ↗ | Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2015-03-01 | This is an open label, single-dose, pharmacokinetic study in 9 obese and 9 age-, sex-, ideal body weight- matched non-obese subjects. Qualifying subjects who have completed an informed consent will receive a single intravenous dose of tedizolid with the collection of 11 blood samples over 72 hours post dose. |
| NCT02342418 ↗ | Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults | Completed | Albany College of Pharmacy and Health Sciences | Phase 4 | 2015-03-01 | This is an open label, single-dose, pharmacokinetic study in 9 obese and 9 age-, sex-, ideal body weight- matched non-obese subjects. Qualifying subjects who have completed an informed consent will receive a single intravenous dose of tedizolid with the collection of 11 blood samples over 72 hours post dose. |
| NCT02342418 ↗ | Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults | Completed | Amit.Pai | Phase 4 | 2015-03-01 | This is an open label, single-dose, pharmacokinetic study in 9 obese and 9 age-, sex-, ideal body weight- matched non-obese subjects. Qualifying subjects who have completed an informed consent will receive a single intravenous dose of tedizolid with the collection of 11 blood samples over 72 hours post dose. |
| NCT02620787 ↗ | Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis | Completed | Merck Sharp & Dohme Corp. | Phase 1 | 2016-02-23 | This study will determine the tissue penetration of tedizolid (Sivextro, Merck & Co.), a novel oxazolidinone antibiotic, into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will be compared with a group of healthy volunteer control participants. |
| NCT02620787 ↗ | Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis | Completed | Hartford Hospital | Phase 1 | 2016-02-23 | This study will determine the tissue penetration of tedizolid (Sivextro, Merck & Co.), a novel oxazolidinone antibiotic, into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will be compared with a group of healthy volunteer control participants. |
| NCT02750761 ↗ | A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013) | Completed | Merck Sharp & Dohme Corp. | Phase 1 | 2016-05-02 | This is a study to assess the pharmacokinetics (PK) of tedizolid phosphate and its active metabolite, tedizolid, and the safety of tedizolid phosphate following administration of a single IV (Part A) or oral suspension (Part B) administration to hospitalized participants ages 6 to <12 years (Groups 1 and 3, respectively), and 2 to <6 years (Groups 2 and 4, respectively). |
| NCT03009045 ↗ | Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections | Active, not recruiting | Los Angeles Biomedical Research Institute | Phase 2 | 2017-02-06 | The problem of interest is that doctors are looking for new antibiotic treatments for bone and joint infections. Treatment for bone and joint infection is not standardized, which allows a wide range of antibiotic therapy to potentially be given. A type of bacteria called S. aureus is the most common cause of bone and joint infection. Methicillin resistant S. aureus (MRSA) is a type of bacteria that is not killed by some antibiotics, and it is increasingly common in U.S. and non-U.S. medical centers. This problem will be studied by investigating whether an antibiotic called tedizolid is tolerable, safe and effective to treat bone and joint infections. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for sivextro
Condition Name
Clinical Trial Locations for sivextro
Trials by Country
Clinical Trial Progress for sivextro
Clinical Trial Phase
Clinical Trial Sponsors for sivextro
Sponsor Name
